Hoptocopter/iStock

We’re Not Ready for Another Pandemic

The next big plague is coming, and despite making progress on pandemic preparedness, the U.S. might still suffer mass casualties. Here’s why.

Ominous pathogens seem to arrive every few years: SARS in 2003, swine flu in 2009, Ebola in 2014Zika in 2016COVID-19 in 2019. The World Health Organization calls these viral threats “Disease X,” both to encourage policy makers to think broadly about what the next pandemic might be, and because it could be anything. At this rate, 2025 is not looking good.

After an inept coronavirus response, will the United States do better when the next pandemic strikes? Experts generally agree that America learned from the past year, and that the next public-health crisis won’t be quite as bewildering. But America’s pandemic preparedness still has major gaps, some of which are too big for any one administration to fix. In recent weeks, I’ve called back many of the experts I interviewed over the past 18 months about masks, testing, contact tracing, quarantine, and more. I asked them, “Are we ready for another one?” The short answer is “Not quite.” The long answer is that being truly “ready” will be harder than anyone realizes.

Public-health Capacity

The U.S. is notorious for spending oodles on health care, but health care has little to do with stopping the spread of infectious diseases. When a person has strep throat, they go to the doctor; when a nation faces an epidemic, it turns to public-health workers. But one major reason the U.S. struggled to contact tracewas that budget cuts following the 2008 recession had eviscerated the nation’s public-health departments. Spending on state and local public-health departments has declined by 16 and 18 percent, respectively, since 2010, according to an analysis by Kaiser Health News and the Associated Press. Public-health departments’ data systems are especially outdated, which means that public-health workers have trouble tracking people’s vaccine status, counting COVID-19 deaths, or sharing data across state lines.

The American Rescue Plan, which was signed by President Joe Biden in March, dedicates $7.7 billion to hiring and training more public-health workers to perform tasks such as contact tracing and vaccination. Several experts commended this cash infusion, but they said what’s really needed is a larger annual public-health budget. Public-health departments can’t hire people based on a onetime surge of money. Just like businesses, they need annual revenue in order to make payroll. “A lot of states are not going to hire people unless they know that there’s a secure, ongoing level of funding,” Marcus Plescia, the chief medical officer at the Association of State and Territorial Health Officials, told me. That would need to come from Congress, a body that is not known for acting swiftly and boldly.

Testing

In March of last year, I explained that the U.S. was behind on coronavirus testing because the FDA’s authorization process for new types of lab tests—called an emergency use authorization, or EUA—was too slow. “The speed of this virus versus the speed of the FDA and the EUA process is mismatched,” Alex Greninger, the assistant director of the virology division at the University of Washington Medical Center, told me at the time.

After these early testing bungles, the FDA changed its authorization process so that labs could spin up tests more quickly. But testing for Disease X is not guaranteed to go more smoothly. The FDA is answerable to whichever administration is in charge at the moment, and the next pandemic might happen under the watch of President Donald Trump Jr., not President Biden. A president might be incentivized to slow testing so that the overall rates of infection look better—and indeed, President Donald Trump reportedly did this.

Another challenge that labs faced this time was getting a sample of the coronavirus out of China, where it originated and where controls on viral-sample shipping are strict. When I called Greninger back recently, he said he hopes that whoever is at the helm of the FDA during the next crisis will allow labs to use the virus’s genetic sequence, which is easier to obtain than a live sample, as the initial way of proving that their test works. (In response to a request for comment, an FDA spokesperson said that in the future, “if there are no available clinical specimens, FDA will consider the best approach to allow for validation with the most appropriate means available, for a limited time until clinical specimens become available.”)

Other testing reforms would be helpful too. The Health and Human Services Department needs to do a better job of coordinating testing among public-health labs, academic labs, and commercial labs, all of which were working on different kinds of tests at the beginning of this pandemic, Scott Becker, the CEO of the Association of Public Health Laboratories, told me. The federal government should also be proactively monitoring wastewater for signs of an emerging virus, not relying on people to volunteer for testing, says Ralph Catalano, a public-health professor at UC Berkeley. These steps would be wise, but they hinge on the wisdom of the people in power when Disease X hits.

The Mask Shortage

As Americans were learning about the coronavirus pandemic, they also learned of something called “the national stockpile,” which held a strategic reserve of N95 masks. Or at least it was supposed to. It turned out that the federal government had distributed 85 million N95s during the 2009 swine-flu pandemic, and that supply was never replenished. That led to a shortage of masks in 2020 just as health-care workers needed them most.

For now, that shortage has been alleviated. Last year, the federal government bought 325 million more N95s, said Dan Glucksman, the senior director for policy at the International Safety Equipment Association, which develops standards for personal protective equipment.

In general, the Biden administration has shown “a commitment to a very data-driven, scientific approach to planning,” Charles Johnson, the president of the ISEA, said. But Glucksman and Johnson told me the administration could improve the stockpile further by having mask manufacturers rotate out the mask supply regularly so that it never expires. (N95 masks expire after about five years.) And to combat the hoards of N95 counterfeiters, Biden would do well to establish a White House–level office to fight fakes, they said.

Quarantine

Americans were supposed to stay home for two weeks if they tested positive for COVID-19 or were exposed to it, but months into the pandemic, it became clearthat they weren’t actually quarantining. The reason many people didn’t quarantine was sad and banal: They didn’t have paid time off from work. “We hear people say, ‘I have to work; I have to have my income,’” Ray Przybelski, the director of the Portage County Health and Human Services Department, in Wisconsin, told me in December.

Throughout the pandemic, the federal government did pass several laws that allowed Americans to stay home from work if they were sick with COVID-19 or had to take care of children who were home from school. The concept of paid time off was so new to Americans that many didn’t realize they could take it. But those provisions have now expired, and that leaves America as, once again, the only industrialized country without mandatory, national paid leave. If paid leave isn’t established through legislation before the next pandemic, Americans will find themselves in the same situation, dragging themselves into work and spreading pathogens behind them.

The States

Americans’ experience of the pandemic was largely determined by the state they lived in. Texans were allowed to stop wearing masks on March 10, 2021, when less than 10 percent of the U.S. population had been fully vaccinated. Hawaiians, meanwhile, were required to keep wearing masks indoors as of May 26, when 40 percent of Americans had been fully vaccinated. Last April, a New Yorker might have huddled alone in her tiny apartment while her relatives in South Dakota, which never issued a stay-at-home order, sat in a casino as though it were a normal spring day. The entire pandemic was a bizarro choose-your-own-adventure story in which governors did most of the choosing.

The Trump administration’s unwillingness to have the federal government take the lead made local public-health officials’ job harder. Contact tracing became a brand-new, massive undertaking thrust on each state overnight. “States were left to figure out contact tracing themselves,” said Steve Waters, the head of Contrace, which helps connect contact tracers with health departments.

The Biden administration believes that the federal government is a necessary leader in pandemic response, and will therefore be better positioned to coordinate state actions if Disease X arrives on its watch. But the ability of the government—any government—to handle a pandemic will be limited in a country where federalism and individualism are prized. Other countries have a minister of health; the U.S. has a weak CDC that makes suggestions states can follow or not. “The public-health response has to be unified across the country, must be guided by national leadership and national direction,” Wafaa El-Sadr, a professor of epidemiology and medicine at Columbia University, told me. “This is almost impossible in the face of limited authority of the CDC over states and the autonomy of states in making their own decisions, often due to political imperatives.”

El-Sadr suggested that, in emergencies such as pandemics, perhaps the CDC could temporarily take on a more “directive” role, telling state leaders exactly what to do. But given the politicization of even cloth face masks and free vaccines, that’s highly unlikely to happen.

She also brought up something that will take more than one presidential administration to fix: A lot of Americans died because “we don’t have a healthy population overall,” El-Sadr said. America has a high rate of obesity, a high rate of poverty, a high rate of uninsurance, and now, a high rate of anti-vaccine conspiracism. Pandemics exploit the vulnerabilities that we’ve never bothered to shore up. We may not know what Disease X will be, but it knows exactly where to hit us.

This article was originally published in The Atlantic. Sign up for their newsletter

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.